Schizophrenia Market Information: By Diagnosis (Blood and Urine Tests, Brain Imaging, and Vision Testing), Treatment Type (Surgery, Radiation Therapy, and Medications), End User (Hospitals, Clinics, and Diagnostic Centers) - Global Forecast till 2023

Market Scenario

Schizophrenia is a chronic and severe mental disorder which affects the patients’ thinking ability. People suffering with schizophrenia, may have difficulty in understanding the different between what is real and what is imaginary. Additionally, people suffering from this illness, need to follow a long term treatment to get effective results. Mostly schizophrenia occurs to the population aged from 16 to 30 years. In rare cases, children too are diagnosed with schizophrenia.

Although the causes of Schizophrenia are still unclear, but some suggest that the cause of this disease include genetics, biology, possible viral infections, and immune disorders. It can be recognized if any one shows symptoms such as, hallucination, delusion, and abnormal behavior.

The schizophrenia market growth is majorly attributed to the increasing patient population suffering with this disease. According to WHO, in 2016, more than 21 million people around the world were diagnosed with schizophrenia. Additionally people with schizophrenia have 2-2.5 % more chances to die earlier than the general population.

A research study published in WHO, in 2016, stated that schizophrenia is more common among males in comparison to females, around 12 million men and 9 million women were diagnosed with schizophrenia.

Moreover, uses of evidence-based technical guidance, tools and training packages for expanding the services in the developing countries are adding fuel to the schizophrenia market. However, majority of the people with this disease in the developing countries are unable to get the treatment owing to lack of effective structure for the treatment in mental hospitals. Increase in number of patients seeking treatment and the rising demand for improved healthcare infrastructure are expected to drive the market.

The global schizophrenia market is expected to grow at a CAGR of 3.2 % during the forecast period 2017-2023.

Intended Audience

- Companies into Schizophrenia
- Research and Development (R&D) Companies
- Independent Research Laboratories
- Market Research and Consulting Service Providers
- Medical Research Laboratories

Figure: Global Schizophrenia Market, By Region Market Share, 2016 (%)
Sources: Annual reports, Press release, White paper, Company presentation

Segmentations

The global schizophrenia market is segmented on the basis of by diagnosis, by treatment type, and by end user.

On the basis of the diagnosis, it is segmented into blood and urine tests, brain imaging, vision testing, and others.

On the basis of the treatment type, it is segmented into surgery, radiation therapy, medications, and others.

On the basis of the end user, it is segmented into hospitals, clinics, diagnostic centers, rehabilitation centers and others.

Regional Analysis

The Americas dominate the global schizophrenia market owing to better treatment availability, high healthcare expenditure, and increasing government support for research & development. Furthermore, strict rule introduce by WHO, will leads the market of schizophrenia.

Europe holds the second position in the global schizophrenia market owing to the government support for research & development and availability of funds for research. This is expected to continue to drive the European market over the forecasted period. For instance, countries like Germany and France are increasing investment in the healthcare domain which is poised to propel the schizophrenia market.

Asia Pacific is the fastest growing schizophrenia market owing to the presence of rapidly developing healthcare technology, huge patient population, and high healthcare expenditure. Moreover, WHO's Mental Health Gap Action Programme, launched in 2008, uses evidence-based technical guidance, tools and training packages to expand service especially in the developing countries like India, Iran, Pakistan, Tanzania. Furthermore, WHO initiative for training primary health-care personnel, providing access to essential drugs, and supporting families in providing home care lead the market growth of the schizophrenia in the region.

On the other hand, in the Middle East and Africa, blood disorders have become a huge problem due to limited screening, ignorance of diseases, and poor access to treatment.

Key Players

Some of key the players in the market are Minerva Neurosciences (U.S.), Promentis Pharmaceuticals, Inc. (U.S.), Bristol-Myers Squibb (U.S.), PsychoGenics Inc. (U.S.), Vineuro Pharmaceuticals, Novartis AG (Switzerland), Merz Pharma GmbH & Co. KGaA (Germany), AbbVie Inc. (U.S.), Eli-Lilly and Company (U.S.), AstraZeneca Plc (U.K)

Research Methodology
Sources: Annual reports, Press release, White paper, and Company presentation

Contents:

Table of Content

1. Report Prologue

2. Market Introduction
   2.1 Definition
   2.2 Scope of the Study
   2.2.1 Research Objective
   2.2.2 Assumptions
   2.2.3 Limitations

3. Research Methodology
   3.1 Introduction
   3.2 Primary Research
   3.3 Secondary research
   3.4 Market Size Estimation

4. Market Dynamics
   4.1 Drivers
   4.2 Restraints
   4.3 Opportunities
   4.4 Challenges
   4.5 Macroeconomic Indicators
   4.6 Technology Trends & Assessment

5. Market Factor Analysis
   5.1 Porters Five Forces Analysis
      5.1.1 Bargaining Power of Suppliers
      5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis

6. Global Schizophrenia Market, by Diagnosis

6.1 Introduction
6.2 Blood and Urine Tests
6.2.1 Market Estimates & Forecast, 2017-2023
6.3 Brain Imaging
6.3.1 Market Estimates & Forecast, 2017-2023
6.4 Vision Testing
6.4.1 Market Estimates & Forecast, 2017-2023
6.5 Others
6.5.1 Market Estimates & Forecast, 2017-2023

7. Global Schizophrenia Market, by Treatment type

7.1 Introduction
7.2 Surgery
7.2.1 Market Estimates & Forecast, 2017-2023
7.3 Radiation Therapy
7.3.1 Market Estimates & Forecast, 2017-2023
7.4 Medications
7.4.1 Market Estimates & Forecast, 2017-2023
7.5 Others
7.5.1 Market Estimates & Forecast, 2017-2023

8. Global Schizophrenia Market, by End User

8.1 Introduction
8.2 Hospitals
8.2.1 Market Estimates & Forecast, 2017-2023
8.3 Clinics
8.3.1 Market Estimates & Forecast, 2017-2023
8.4 Diagnostic Centers
8.4.1 Market Estimates & Forecast, 2017-2023
8.5 Rehabilitation Centers
8.5.1 Market Estimates & Forecast, 2017-2023
8.6 Others
8.6.1 Market Estimates & Forecast, 2017-2023

9. Global Schizophrenia Market, by Region

9.1 Introduction
9.2 Americas
9.2.1 North America
9.2.1.1 U.S.
9.2.1.2 Canada
9.2.2 South America
9.3 Europe
9.3.1 Western Europe
9.3.1.1 Germany
9.3.1.2 France
9.3.1.3 U.K
9.3.1.4 Italy
9.3.1.5 Spain
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Republic of Korea
9.4.6 Rest of Asia Pacific
9.5 The Middle East & Africa
9.5.1 United Arab Emirates
9.5.2 Saudi Arabia
9.5.3 Oman
9.5.4 Kuwait
9.5.5 Qatar
9.5.6 Rest of the Middle East & Africa

10 Company Landscape
10.1 Introduction
10.2 Market Share Analysis
10.3 Key Development & Strategies
10.3.1 Key Developments

11 Company Profiles
11.1 Minerva Neurosciences
11.1.1 Company Overview
11.1.2 Product Overview
11.1.3 Financials
11.1.4 SWOT Analysis
11.2 Promentis Pharmaceuticals, Inc.
11.2.1 Company Overview
11.2.2 Product Overview
11.2.3 Financial Overview
11.2.4 Key Developments
11.2.5 SWOT Analysis
11.3 Bristol-Myers Squibb
11.3.1 Company Overview
11.3.2 Product Overview
11.3.3 Financial Overview
11.3.4 Key Development
11.3.5 SWOT Analysis
11.4 PsychoGenics Inc.
11.4.1 Company Overview
11.4.2 Product Overview
11.4.3 Financial Overview
11.4.4 Key Development
11.4.5 SWOT Analysis
11.5 Vineuro Pharmaceuticals
11.5.1 Company Overview
11.5.2 Product Overview
11.5.3 Financial overview
11.5.4 Key Developments
11.6 Novartis Ag
11.6.1 Company Overview
11.6.2 Product Overview
11.6.3 Financial Overview
11.6.4 Key Developments
11.7 Merz Pharma GmbH & Co. KGaA
11.7.1 Overview
11.7.2 Product Overview
11.7.3 Financials
11.7.4 Key Developments
11.7.5 SWOT Analysis
11.8 Others

12 MRFR Conclusion
12.1 Key Findings
12.1.1 From CEO’s View Point
12.1.2 Unmet Needs of the Market
12.2 Key Companies to Watch
12.3 Prediction of Pharmaceutical Industry

13 Appendix

LIST OF TABLES
Table 1 Schizophrenia market Industry Synopsis, 2017-2023
Table 2 Global Schizophrenia Market Estimates and Forecast, 2017-2023, (USD Million)
Table 3 Global Schizophrenia Market by Region, 2017-2023, (USD Million)
Table 4 Global Schizophrenia Market by Diagnosis, 2017-2023, (USD Million)
Table 5 Global Schizophrenia Market by Treatment type, 2017-2023, (USD Million)
Table 6 Global Schizophrenia Market by End Users, 2017-2023, (USD Million)
Table 7 North America Schizophrenia Market by Diagnosis, 2017-2023, (USD Million)
Table 8 North America Schizophrenia Market by Treatment type, 2017-2023, (USD Million)
Table 9 North America Schizophrenia Market by End Users, 2017-2023, (USD Million)
Table 10 US Schizophrenia Market by Diagnosis, 2017-2023, (USD Million)
Table 11 US Schizophrenia Market by Treatment type, 2017-2023, (USD Million)
Table 12 US Schizophrenia Market by End Users, 2017-2023, (USD Million)
Table 13 Canada Schizophrenia Market by Diagnosis, 2017-2023, (USD Million)
Table 14 Canada Schizophrenia Market by Treatment type, 2017-2023, (USD Million)
Table 15 Canada Schizophrenia Market by End Users, 2017-2023, (USD Million)
Table 16 South America Schizophrenia Market by Diagnosis, 2017-2023, (USD Million)
Table 17 South America Schizophrenia Market by Treatment type, 2017-2023, (USD Million)
Table 18 South America Schizophrenia Market by End Users, 2017-2023, (USD Million)
Table 19 Europe Schizophrenia Market by Diagnosis, 2017-2023, (USD Million)
Table 20 Europe Schizophrenia Market by Treatment type, 2017-2023, (USD Million)
Table 21 Europe Schizophrenia Market by End Users, 2017-2023, (USD Million)
Table 22 Western Europe Schizophrenia Market by Diagnosis, 2017-2023, (USD Million)
Table 23 Western Europe Schizophrenia Market by Treatment type, 2017-2023, (USD Million)
Table 24 Western Europe Schizophrenia Market by End Users, 2017-2023, (USD Million)
Table 25 Eastern Europe Schizophrenia Market by Diagnosis, 2017-2023, (USD Million)
Table 26 Eastern Europe Schizophrenia Market by Treatment type, 2017-2023, (USD Million)
Table 27 Eastern Europe Schizophrenia Market by End Users, 2017-2023, (USD Million)
Table 28 Asia Pacific Schizophrenia Market by Diagnosis, 2017-2023, (USD Million)
Table 29 Asia Pacific Schizophrenia Market by Treatment type, 2017-2023, (USD Million)
Table 30 Asia Pacific Schizophrenia Market by End Users, 2017-2023, (USD Million)
Table 31 Middle East & Africa Schizophrenia Market by Diagnosis, 2017-2023, (USD Million)
Table 32 Middle East & Africa Schizophrenia Market by Treatment type, 2017-2023, (USD Million)
Table 33 Middle East & Africa Schizophrenia Market by End Users, 2017-2023, (USD Million)

LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation for Global Schizophrenia Market
Figure 3 Segmentation Market Dynamics for Schizophrenia Market
Figure 4 Global Schizophrenia Market Share, by Diagnosis 2016
Figure 5 Global Schizophrenia Market Share, by Treatment type 2016
Figure 6 Global Schizophrenia Market Share, by End Users, 2016
Figure 7 Global Schizophrenia Market Share, by Region, 2016
Figure 8 America Schizophrenia Market Share, by Country, 2016
Figure 9 Europe Schizophrenia Market Share, by Country, 2016
Figure 10 Asia Pacific Schizophrenia Market Share, by Country, 2016
Figure 11 Middle East & Africa Schizophrenia Market Share, by Country, 2016
Figure 12 Global Schizophrenia Market: Company Share Analysis, 2016 (%)
Figure 13 Minerva Neurosciences: Key Financials
Figure 14 Minerva Neurosciences: Segmental Revenue
Figure 15 Minerva Neurosciences: Geographical Revenue
Figure 16 Promentis Pharmaceuticals, Inc.: Key Financials
Figure 17 Promentis Pharmaceuticals, Inc.: Segmental Revenue
Figure 18 Promentis Pharmaceuticals, Inc.: Geographical Revenue
Figure 19 Bristol-Myers Squibb: Key Financials
Figure 20 Bristol-Myers Squibb: Segmental Revenue
Figure 21 Bristol-Myers Squibb: Geographical Revenue
Figure 22 PsychoGenics Inc.: Key Financials
Figure 23 PsychoGenics Inc.: Segmental Revenue
Figure 24 PsychoGenics Inc.: Geographical Revenue
Figure 25 Vineuro Pharmaceuticals: Key Financials
Figure 26 Vineuro Pharmaceuticals: Segmental Revenue
Figure 27 Vineuro Pharmaceuticals: Geographical Revenue
Figure 28 Novartis AG: Key Financials
Figure 29 Novartis AG: Segmental Revenue
Figure 30 Novartis AG: Geographical Revenue
Figure 31 Merz Pharma GmbH & Co. KGaA: Key Financials
Figure 32 Merz Pharma GmbH & Co. KGaA: Segmental Revenue
Figure 33 Merz Pharma GmbH & Co. KGaA: Geographical Revenue